Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Income from Continuing Operations (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Income from Continuing Operations for 11 consecutive years, with 117875649.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations changed N/A to 117875649.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 141364069.0, a N/A change, with the full-year FY2025 number at 153942000.0, down 293.67% from a year prior.
  • Income from Continuing Operations was 117875649.0 for Q4 2025 at Crescent Biopharma, down from 2343736.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 2343736.0 in Q1 2025 to a low of 117875649.0 in Q4 2025.
  • A 5-year average of 17595082.06 and a median of 10736667.0 in 2024 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 86.28% in 2021, then surged 78.17% in 2025.
  • Crescent Biopharma's Income from Continuing Operations stood at 17421796.0 in 2021, then soared by 41.2% to 10244356.0 in 2022, then rose by 11.38% to 9078640.0 in 2023, then fell by 21.71% to 11049278.0 in 2024, then crashed by 966.82% to 117875649.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Income from Continuing Operations are 117875649.0 (Q4 2025), 2343736.0 (Q1 2025), and 11049278.0 (Q3 2024).